QR Code

Utility of Soluble CD163 in the Clinical Management of Patients With Kawasaki Disease

Objective: Intravenous immunoglobulin (IVIG) therapy is a useful first-line treatment for Kawasaki disease (KD); however, 10–20% of patients fail to respond and require additional IVIG. Soluble CD163 (sCD163) is considered a biomarker for macrophage activation. There are no reports measuring serum s...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Yoshihiro Azuma, Yasuo Suzuki, Seigo Okada, Chie Matsuguma, Hiroyuki Wakiguchi, Yuji Ohnishi, Takashi Furuta, Akiko Miyake, Hiroki Yasudo, Kiyoshi Ichihara, Shouichi Ohga, Shunji Hasegawa
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Frontiers Media S.A. 2020-04-01
Rangatū:Frontiers in Pediatrics
Ngā marau:
intravenous immunoglobulin
Kawasaki disease
macrophage
soluble CD163
sCD163
Urunga tuihono:https://www.frontiersin.org/article/10.3389/fped.2020.00148/full
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite